Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harold E Bays

Showing results (1-10 of 158) with videos related to

Pageof 16
Sort By:
Journal of Clinical Lipidology|April 9, 2016
A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goalsHarold E Bays
Expert Review of Cardiovascular Therapy|November 11, 2009
Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic diseaseHarold E Bays
The American Journal of Cardiology|March 21, 2007
Safety considerations with omega-3 fatty acid therapyHarold E Bays
Expert Review of Cardiovascular Therapy|March 29, 2011
Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug developmentHarold E Bays
Expert Review of Cardiovascular Therapy|July 1, 2004
Extended-release niacin/lovastatin: the first combination product for dyslipidemiaHarold E Bays
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|July 19, 2012
Long-term (52-78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patientsHarold E Bays
Obesity Research|September 2, 2004
Current and investigational antiobesity agents and obesity therapeutic treatment targetsHarold E Bays
Managed Care (Langhorne, Pa.)|November 17, 2004
Metabolic syndrome: what might be occurring?Harold E Bays
The American Journal of Medicine|December 27, 2008
"Sick fat," metabolic disease, and atherosclerosisHarold E Bays
Journal of Clinical Lipidology|April 9, 2016
A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessmentHarold E Bays
Pageof 16

Showing results (1-10 of 158) with videos related to

Sort By:
Pageof 16
Journal of Clinical Lipidology|April 9, 2016
A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goalsHarold E Bays
Expert Review of Cardiovascular Therapy|November 11, 2009
Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic diseaseHarold E Bays
The American Journal of Cardiology|March 21, 2007
Safety considerations with omega-3 fatty acid therapyHarold E Bays
Expert Review of Cardiovascular Therapy|March 29, 2011
Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug developmentHarold E Bays
Expert Review of Cardiovascular Therapy|July 1, 2004
Extended-release niacin/lovastatin: the first combination product for dyslipidemiaHarold E Bays
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|July 19, 2012
Long-term (52-78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patientsHarold E Bays
Obesity Research|September 2, 2004
Current and investigational antiobesity agents and obesity therapeutic treatment targetsHarold E Bays
Managed Care (Langhorne, Pa.)|November 17, 2004
Metabolic syndrome: what might be occurring?Harold E Bays
The American Journal of Medicine|December 27, 2008
"Sick fat," metabolic disease, and atherosclerosisHarold E Bays
Journal of Clinical Lipidology|April 9, 2016
A lipidologist perspective of global lipid guidelines and recommendations, part 1: Lipid treatment targets and risk assessmentHarold E Bays
Pageof 16